TypeOnline Course
Student Enrolled1
Price$390 / Rs. 19500
Buy NowBook Now

Admission Process

Admission Process

Sign in or create account at www.nckpharma.com with all details and make the course fees payment to start the course

Sign Up Now

biosimilar course

Introduction

Features

Duration

Content Deliverables

Course Syllabus

Admission Process

Course Code: KPE-C-22

Course Title: KPE’s Certificate Program in Biologic (Biotech & Biosimilar) Regulation & Strategic Management

Course Objective: Working Professionals & B.Pharm/D.Pharm/ B.Sc/ Any graduates or those who are in 3rd / final year of those courses, who want to make career in biopharmaceutical marketing, business development and regulatory affairs, can pursue the course.

Nature of the Course: Distance & e-Learning

Course Description:This online course – KPE’s Certificate Program in Biologic (Biotech & Biosimilar) Regulation & Strategic Management training course utilizes interactive learning tools to guide each participant through the steps of the biotech and biosimilar drugs development process and regulation. The course is designed to challenge users to apply what they have learned through the use of interactive exercises, reflection questions, expert live chat and a final assessment at the end of the course.

The course can be completed at any pace, allowing the user to stop and start at their leisure.

Features of the Course:

1. Comprehensive study material covering all important aspects of Biosimilar regulation.

2. Understanding/ Decision Making/ Strategy Creation in the field of Biosimilar regulation.

3. Live Pharma  Case Study –  File for easy understanding in biologics-biosimilar regulations and its implications.

4. Specialized modules on demand

5. Certificate will be issued at the end of the course.

1 Month

Course Content Deliverables:

1. Printable Module can be downloaded by visiting to your dashboard.

2. Access the E-Modules online with user id and password.

3. Attend e-lectures.

4. Access to case study file online

5. All e-study material contains self assessment computer based test.

6. Flexible online final examination.

Printable Modules 

Module 1 Drug Discovery and Development Process
Module 2 Biopharmaceutical – Detailed Understanding 
Module 3 Biosimilar 
Module 4 Biosimilar Development Process
Module 5 Biopharmaceutical Industry 
Module 6 EU Biosimilar guidelines
Module 7 Biosimilar guidelines in different regions 
Module 8 Licensing and Technology Transfer in Biopharmaceutical Industry 
Module 9 Biopharma Case Studies

Other than books, you will also get the online modules – electures, case studies etc. which you can access by login with your access credentials. 

Biologic & Biosimilar Regulation and Registration course is structured as follows:

  • Biotech Drug Development Process
    Overview of the development of a biotech product – clarify the difference between synthetic drugs, biologics and biotech products .
  • Biotech Regulation – Key Understanding
    US drugs vs. Biologics Law: Understand the differences in regulatory philosophy between small molecules and biotech product regulation
  • Preclinical and Clinical Research Design
    An examination of preclinical and clinical research designs. Emphasis is on identifying and addressing challenges associated with elements of good laboratory and clinical practice and qualifying and managing a laboratory for a clinical trial. Discussion covers best practices for planning research and collecting, analyzing, and reporting data from drug/device development studies.
  • Analytical techniques for the Biotech Drugs
    Understand the need for using a range of analytical methods in the characterization of biotech product.
  • Product Life Cycle Approval, Production, and Marketing for Bio-pharmaceuticals
    An in-depth study of the product life cycle for biopharmaceuticals. Focus is on the various stages within the life cycle from conceptualization of a product pipeline in research and development through postmarket surveillance and production. Topics include regulatory submission, approval, production, and the postmarket environment for both drugs and devices. Challenges surrounding the approval and naming of follow-on biologics are addressed. Discussion also covers combination medicines, the stages of a drug pipeline and risk assessment at each stage, and the decreasing productivity of the drug pipeline. The role of a contract research organization in testing and approval is explained, and the nature of the support services they provide to the biotechnology and devices industry is explored.
  • Global Biotechnology Business
    Topics include international biotechnology issues, global harmonization efforts, and the cultural impact of biotechnologies. Discussion also covers domestic and International business considerations and international regulatory requirements.

Practical Case Studies – Applications of Biotech Regulatory Affairs
A capstone study of regulatory affairs related to the biotechnology industry that integrates knowledge and skills gained from previous study.

  • Introduction to Global biopharmaceutical Industry. Overview of General Regulation.
  • Biotech Drug Discovery and Development Process
  • Biotech Drugs Classification. Important classes.
  • Introduction to Biotech Industry – Global and Indian. Leading Biotech companies and their product and pipeline analysis
  • Regulation in Biotech Industry
  • Overview of patent in biotech industry.
  • Introduction to Biosimilar. Meaning of Biosimilar vs. Follow on biologics.
  • Difference between biosimilar and generic drugs.
  • Key important issues in Biotech and biosimilar product manufacturing.
  • GMP requirements in biotech industry.
  • General approval process of biosimilar products.
  • Biosimilar Development project management – timeline creation with business outcome

Country specific regulation  in Biosimilar Products –

  • Biotech and Biosimilar regulation in US
  • Biotech and Biosimilar regulation in EU
  • Major differences in US and EU
  • Biosimilar regulation and registration in India
  • Biosimilar policies in the UK, Use of biosimilars in Europe, EMEA regulation on biosimilar
  • Registration of biosimilar in other different countries

FAQ RELATED TO THE COURSE

Frequently asked questions

Read FAQs

ADMISSION PROCESS

Course Flow and Timeline

Section 1Introduction to Biopharmaceuticals
Lecture 1Introduction: Biopharmaceuticals
Lecture 2Classification & Detailed Understanding on Biopharmaceuticals
Lecture 3Introduction to Biosimilar
Lecture 4Chemical Drugs Vs. Biologic Drugs
Lecture 5Principle of Naming of Biologics
Section 2Global Biopharmaceutical Market
Lecture 6Current Trends in Biopharmaceutical Market
Lecture 7Dynamics of Biopharmaceutical Market
Lecture 8Challenges of Biopharmaceutical Industry
Lecture 9Biopharmaceutical Market Segmentation
Lecture 10Market Share of Different Class of Biopharmaceuticals
Lecture 11Blockbuster Biologic - Classifications, Indications, Global Sales
Lecture 12Market Understanding: Leading Biosimilar Companies
Lecture 13Market Understanding: Top Leading Brands
Section 3Detailed Understanding of different therapeutic classes of Biologics
Lecture 14Recombinant Proteins
Lecture 15Monoclonal Antibodies Vs. Polyclonal Antibodies
Lecture 16Monoclonal Antibodies : Detailed Understanding
Lecture 17Synthetic Immunomodulators
Lecture 18Production of Monoclonal Antibodies
Lecture 19Cytokines
Lecture 20Interferon
Lecture 21Erythropoiesis-stimulating agent (EPOs)
Section 4Biopharmaceutical Regulatory Approval Process
Lecture 22New Biopharmaceutical Approval process Vs. Bissimilar Vs. New Molecule Vs. Generic Drug Approval Process
Lecture 23Biologic License Application (BLA)
Lecture 24Biosimilar Approval process
Lecture 25Difference : Drugs Vs. Biopharmaceutical Approval process
Lecture 26Nomenclature of biosimilars
Lecture 27Vaccine Development Process
Lecture 28Pricing and cost effectiveness of biosimilars
Lecture 29Exclusivity Protections for Biopharmaceuticals
Lecture 30Risk Evaluation and Mitigation Strategy (REMS)
Lecture 31Learning from New Drug Approvals - 2016
Lecture 32PDUFA & BsUFA For Biologics
Lecture 33Review : 351(a) vs. 351(k) pathway
Lecture 34Advance Learning on 505B2 Pathway
Lecture 35FDA Forms and How to fill the resources
Lecture 36Strategic Discussion: PreIND, EOP1, EOP2 - What to expect !
Section 5Bio Manufacturing Process
Lecture 37Stages of Biosimilar development
Lecture 38Challenges in manufacturing of biosimilar
Lecture 39Concept of Reference Biologics
Lecture 40Detailed Manufacturing Process
Lecture 41Concept of Interchangeability in Biosimilar Development
Lecture 42Studies required for approval of biosimilar
Lecture 43Demonstrating Biosimilarity: A More Complex Task 
Lecture 44Difference between Bioreactor and Fermentor
Section 6Biopharmaceutical Patents - Biosimilar Entry / Exclusivity - Case Learnings
Lecture 45Practical Training on understanding of Biopharmaceutical Patent
Lecture 46Biopharmaceutical Exclusivity / protections
Lecture 47Patent Protection Small Molecules Vs. Innovator Biologics
Lecture 48Regulatory Exclusivity for Small Molecules Vs. Biosimilars
Lecture 49Steps Know How & Key Points - Patent Application
Lecture 50Fundamental Understanding of Patent, Trademark Licensing and related terminology
Section 7Principles for Development of Similar Biologics
Lecture 51Selection of Reference Biologics
Lecture 52Manufacturing Process Development for Biosimilar
Lecture 53Quality Based Considerations for Similar Biologics
Lecture 54Data Requirements for Preclinical Studies
Lecture 55Post-Market Data for Similar Biologics
Section 8Biosimilar Guidelines in Different Regions
Lecture 56WHO Regulatory Guidelines
Lecture 57European Union (EMA)
Lecture 58United States of America (US FDA)
Lecture 59Japan - PMDA
Lecture 60Korea (KFDA)
Lecture 61Canada (Health Canada)
Lecture 62China - SFDA
Lecture 63India (Central Drugs Standard Control Organization)
Lecture 64Jordan (Jordan Food and Drug Administration)
Lecture 65Middle East
Section 9Biosimilar Development to Commercialization : Case Studies
Lecture 66Biosimilar Development Timeline
Lecture 67Case Study New mAB approval: Avelumab for metastatic Merkel Cell Carcinoma (mMCC)
Section 10Biopharmaceutical Strategic Management
Lecture 68Patents Vs. exclusivity
Lecture 69Regulatory Strategies in different phases of Clinical Trial
Lecture 70Advance study on Para IV Filing
Lecture 71Para IV Notices
Lecture 72Evergreening - Patent Life Extension Strategies
Lecture 73Pay For Delay Strategy
Lecture 74In-Licensing Vs. Outlicensing
Lecture 75Leading Biologic Company's Analysis : Strategic Point of view
Lecture 76Strategic alliance Termination / Failure in strategic alliances in biopharmaceutical industry
Lecture 77Compulsory Licensing
Lecture 78Licensing & Technology Transfer
Lecture 79LOE Strategies for Innovator Brands with case study
Lecture 80Paediatric Exclusivity and Paediatric Study Plan Development
Lecture 81Drug Repurposing
Lecture 82Summary of Regulatory & Strategic Differences
Section 11Final Examination
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,